insights_auto
Outlook: 43.3% bullish·20.0% bearish
Go to analysischevron_right
BNTX:NASDAQ
BioNTech SE - ADR
$88.12
arrow_downward
-1.73%(-1.56) 1D
$88.40
arrow_upward
+0.32% (+0.29)bedtimeAfter hours
Closed: Oct 23, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BNTX...
Open
$89.34
High
$89.86
Low
$87.52
Mkt. cap
22.13B
Avg. vol.
1.04M
Volume
838.70K
52-wk high
$123.98
52-wk low
$79.52
EPS
-$7.52
Beta
1.22
Shares outstanding
251.20M
No. of employees
8K
Open
$89.34
High
$89.86
Low
$87.52
Mkt. cap
22.13B
Avg. vol.
1.04M
Volume
838.70K
52-wk high
$123.98
52-wk low
$79.52
EPS
-$7.52
Beta
1.22
Shares outstanding
251.20M
No. of employees
8K
News stories
From web sources and news partners
Yahoo Finance
·
7 hours ago
BioNTech (BNTX) Reworks Phase 3 Breast Cancer Trial Around New Combination Approach
Investing.com Canada
·
11 hours ago
BioNTech, Bristol Myers report lung cancer trial data By Investing.com
Investing.com
·
3 days ago
BioNTech, Gilead collaborate on triple-negative breast cancer trial
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR